Linden Gerard J, Mullally Brian H, Burden Donald J, Lamey Philip-John, Shaw Christopher, Ardill Joy, Lundy Fionnuala T
Oral Science Research Centre, Division of Restorative Dentistry (Periodontics), School of Dentistry, Queen's University of Belfast, Northern Ireland.
J Clin Periodontol. 2002 Jun;29(6):484-9. doi: 10.1034/j.1600-051x.2002.290602.x.
To evaluate the role of the anti-inflammatory neuropeptide vasoactive intestinal peptide (VIP) in periodontal health and disease and to determine the effects of periodontal treatment, resulting in a return to periodontal health, on the levels of VIP in gingival crevicular fluid (GCF).
At baseline, 10 subjects with periodontitis (nine females, one male, mean age 43.0, SD 7.3) started a course of non-surgical periodontal treatment. Clinical indices were measured at one periodontitis and one clinically healthy site at an initial visit and at 8 weeks after the completion of treatment in each subject. A 30-s sample of GCF was collected from each test site using perio paper strips. The volume of GCF was measured and each sample subsequently analysed for VIP by radioimmunoassay. One healthy site was sampled from each member of a control group (10 females, mean age 29.9, SD 8.2 years) with clinically healthy gingiva and no periodontitis.
The clinical condition of all periodontitis sites improved as a result of periodontal treatment. The levels of VIP (pg/30 s sample) in periodontitis-affected sites fell significantly from 302.0 (SD 181.2) at the initial visit to 78.0 (54.4) after treatment, p = 0.007. The reduction in the concentration of VIP (pg/ micro L) in GCF from 524.3 (322.3) to 280.8 (280.2) was not statistically significant. The levels of VIP in clinically healthy sites fell from 115.5.5 (74.3) to 77.8 (32.3), n.s. and the concentration changed little from 883.8 (652.1) to 628.7 (323.3), n.s. There were substantially smaller amounts of VIP (25.8, SD 12.8) pg in healthy sites sampled from control subjects.
VIP is present in GCF in greater quantities in periodontitis-affected than clinically healthy sites. In addition, the reduction in inflammation resulting from effective periodontal treatment is associated with a reduction in the levels of VIP in gingival crevicular fluid.
评估抗炎神经肽血管活性肠肽（VIP）在牙周健康与疾病中的作用，并确定导致牙周恢复健康的牙周治疗对龈沟液（GCF）中VIP水平的影响。
在基线时，10名牙周炎患者（9名女性，1名男性，平均年龄43.0岁，标准差7.3）开始进行非手术牙周治疗。在初次就诊时以及每位患者治疗完成后8周，在一个牙周炎部位和一个临床健康部位测量临床指标。使用牙周试纸条从每个测试部位收集30秒的GCF样本。测量GCF的体积，随后通过放射免疫分析法对每个样本进行VIP分析。从对照组（10名女性，平均年龄29.9岁，标准差8.2岁）中具有临床健康牙龈且无牙周炎的每位成员的一个健康部位取样。
牙周治疗后所有牙周炎部位的临床状况均有所改善。牙周炎受累部位的VIP水平（pg/30秒样本）从初次就诊时的302.0（标准差181.2）显著降至治疗后的78.0（54.4），p = 0.007。GCF中VIP浓度（pg/微升）从524.3（322.3）降至280.8（280.2），差异无统计学意义。临床健康部位的VIP水平从115.5（74.3）降至77.8（32.3），无统计学意义，浓度从883.8（652.1）变化至628.7（323.3），无统计学意义。从对照组受试者的健康部位取样的VIP量（25.8，标准差12.8）pg明显更少。
与临床健康部位相比，牙周炎受累部位的龈沟液中VIP含量更高。此外，有效的牙周治疗导致的炎症减轻与龈沟液中VIP水平降低有关。
